Tarsus Pharmaceuticals (NASDAQ:TARS) Issues Quarterly Earnings Results, Misses Estimates By $12.94 EPS

Tarsus Pharmaceuticals (NASDAQ:TARS) announced its quarterly earnings data on Tuesday. The company reported ($14.40) earnings per share for the quarter, missing the consensus estimate of ($1.46) by ($12.94), FiscalAI reports. The firm had revenue of $194.57 million during the quarter, compared to analysts’ expectations of $187.83 million. Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS traded down $0.68 during trading hours on Tuesday, hitting $72.64. The stock had a trading volume of 752,103 shares, compared to its average volume of 769,028. The firm has a 50-day moving average price of $75.17 and a 200 day moving average price of $67.88. Tarsus Pharmaceuticals has a fifty-two week low of $53.89 and a fifty-two week high of $91.53. The firm has a market capitalization of $3.58 billion, a price-to-earnings ratio of -66.64 and a beta of 0.44. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.17 and a current ratio of 3.20.

Insider Activity at Tarsus Pharmaceuticals

In other news, insider Elizabeth Lin sold 3,180 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $87.50, for a total transaction of $278,250.00. Following the sale, the insider owned 1,590 shares of the company’s stock, valued at approximately $139,125. This represents a 66.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director William J. Phd Link sold 12,500 shares of the company’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $78.38, for a total transaction of $979,750.00. Following the completion of the transaction, the director owned 94,487 shares of the company’s stock, valued at approximately $7,405,891.06. The trade was a 11.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 48,031 shares of company stock valued at $4,004,227. 9.64% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms have weighed in on TARS. Oppenheimer boosted their price target on shares of Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 12th. Barclays initiated coverage on Tarsus Pharmaceuticals in a research note on Wednesday, September 16th. They issued an “overweight” rating and a $110.00 price target on the stock. Mizuho lowered their price target on Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. Jefferies Financial Group increased their price target on shares of Tarsus Pharmaceuticals from $88.00 to $105.00 and gave the stock a “buy” rating in a research report on Tuesday, September 8th. Finally, Guggenheim decreased their price target on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating on the stock in a report on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $100.86.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye diseases with significant unmet medical needs. The company’s portfolio is centered on therapies designed to address conditions affecting the ocular surface and eyelids.

Tarsus’ lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, an eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, an inflammatory eyelid condition associated with an infestation of Demodex mites.